Drug Eluting Balloon Catheters Market: as CMS's new technology add-on payment removes a real reimbursement barrier for the first coronary DCB approved in the United States, every hospital that adds it to formulary now has a Medicare-backed financial case for choosing a leave-nothing-behind balloon over a permanent stent in in-stent restenosis, so the category's US growth curve is shifting from a purely clinical adoption story to a payment-policy-enabled one, and advantage is moving toward device makers whose coating technology and reimbursement position both hold up simultaneously.

The global drug eluting balloon catheters market size was USD 712.4 Million in 2025 and is expected to register a revenue CAGR of 10.1% during the forecast period. Market revenue growth is driven by factors such as the first FDA-approved coronary DCB catalysing US in-stent restenosis treatment conversion, CMS reimbursement policy support removing a key adoption barrier, and sirolimus-eluting balloon platforms extending the category into new peripheral indications. The first driving factor is the FDA approval of the first coronary drug-coated balloon in the United States, which opened an entirely new indication category for US interventional cardiologists. Paclitaxel-coated balloons account for a substantial share of total 2025 market revenue, reflecting the drug class's established position across both the coronary and peripheral segments of the category. The second driving factor is CMS reimbursement policy support, which directly addresses the hospital-level financial barrier that has historically slowed DCB adoption relative to stenting. The third driving factor is sirolimus-eluting balloon platforms extending sustained limus release technology into new peripheral and below-the-knee applications beyond the original paclitaxel-coated category. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single coating technology platform accumulates additional clinical indications and reimbursement designations over its lifecycle, which converts one balloon catheter design into a widening set of billable, payer-supported applications without requiring an entirely new device. Once a coating technology earns its baseline clinical approval, each additional cleared indication or payer reimbursement designation extends the platform's addressable procedure volume without a new device design, so platform value compounds as its indication and reimbursement footprint widens around the same core coating chemistry. As a result, demand and revenue share are concentrating around coating platforms with the broadest combined indication and reimbursement footprint, and the forecast tilts toward established coating technologies extending into new applications rather than new entrants competing on coating chemistry alone. For instance, in August 2025, the Centers for Medicare and Medicaid Services granted a New Technology Add-on Payment designation to Boston Scientific's AGENT paclitaxel-coated balloon, directly extending the reimbursement footprint behind the first FDA-approved coronary DCB in the United States. These are some of the key factors driving revenue growth of the market.

Because coronary DCB technology only recently received its first US approval, the category lacks the multi-decade long-term outcome data that drug-eluting stents have accumulated, and physicians treating standard-risk patients where stenting remains well-established may be cautious about shifting practice patterns until longer-term coronary DCB data accumulates.

Paclitaxel safety scrutiny is a second constraint, because earlier meta-analyses raised safety questions about paclitaxel-coated peripheral devices that, while substantially addressed by subsequent data and regulatory review, continue to influence some physician and health system purchasing caution around paclitaxel-based coating technology specifically.

Procedural technique learning curve is a third constraint, since achieving consistent drug transfer and vessel preparation with a DCB requires different technique than stent deployment, and health systems adopting DCB technology for the first time must invest in physician training that adds friction to the adoption pathway.

These factors substantially limit drug eluting balloon catheters market growth over the forecast period.

The clearest driver of demand is the FDA approval of the first coronary drug-coated balloon in the United States, which opened an entirely new treatment category for physicians managing coronary in-stent restenosis. Treating in-stent restenosis with another stent adds another layer of permanent metal to an artery that has already shown a tendency toward restenosis, so a drug-coated balloon that delivers antiproliferative therapy without leaving additional permanent hardware behind directly addresses a specific clinical need that stenting alone could not solve. Boston Scientific's AGENT paclitaxel-coated balloon received FDA approval in March 2024 as the first coronary DCB in the United States, supported by the AGENT IDE trial that enrolled 600 patients across 40 US sites, and the company has reported that more than 100,000 patients have now been treated globally. The effect on the market is that US interventional cardiologists now have an FDA-approved, leave-nothing-behind treatment option specifically for in-stent restenosis that did not exist in the domestic market before 2024. These are some of the key factors driving revenue growth of the market.

The second driver is CMS reimbursement policy support for coronary DCB technology, which directly addresses the hospital-level financial barrier that has historically slowed adoption of technology that costs more than the alternative it replaces. A New Technology Add-on Payment designation supplements standard Medicare inpatient reimbursement specifically to offset the incremental cost of a new technology during its early adoption period, so a hospital adopting AGENT no longer needs to absorb the full cost differential between a DCB and a comparable stenting procedure out of its own margin. In August 2025, CMS granted New Technology Add-on Payment designation to Boston Scientific's AGENT paclitaxel-coated balloon, directly extending Medicare reimbursement support behind the first FDA-approved coronary DCB in the United States. The effect on the market is that the CMS reimbursement decision removes a specific, quantifiable financial barrier that hospital purchasing committees had previously needed to weigh against AGENT's clinical benefit. These are some of the key factors driving revenue growth of the market.

Boston Scientific's AGENT paclitaxel-coated balloon has now treated more than 100,000 patients globally. CMS's August 2025 reimbursement decision removes the hospital-level cost barrier that had constrained faster US adoption.

The third driver is the extension of sirolimus and limus-based coating technology into peripheral and below-the-knee applications that broaden the category beyond its original paclitaxel-coated coronary and superficial femoral artery indications. Below-the-knee arterial disease presents distinct anatomical and clinical challenges from coronary or superficial femoral artery disease, so a coating platform engineered specifically for sustained limus release in smaller, more distal vessels addresses a genuinely different clinical need than the coronary and larger peripheral indications the category originally targeted. In April 2025, Cordis released new data from two peripheral studies assessing its SELUTION SLR sustained limus release drug-eluting balloon, following the company's 2022 acquisition of MedAlliance, and Medtronic expanded its CE Mark for the Prevail platform in May 2025. The effect on the market is that the addressable clinical indication set for drug-eluting balloon technology continues to widen beyond its original coronary and femoropopliteal application base. These are some of the key factors driving revenue growth of the market.

However, the drug eluting balloon catheters market faces severe adoption constraints from limited long-term outcome data relative to established drug-eluting stents and ongoing paclitaxel safety scrutiny in peripheral applications.

Because coronary DCB technology only recently received its first US approval, the category lacks the multi-decade long-term outcome data that drug-eluting stents have accumulated, and physicians treating standard-risk patients where stenting remains well-established may be cautious about shifting practice patterns until longer-term coronary DCB data accumulates from real-world use.

Paclitaxel safety scrutiny compounds this, because earlier meta-analyses raised safety questions about paclitaxel-coated peripheral devices that, while substantially addressed by subsequent data and regulatory review, continue to influence some physician and health system purchasing caution around paclitaxel-based coating technology specifically, even as sirolimus-based alternatives gain share partly in response.

Procedural technique learning curve is the third constraint, since achieving consistent drug transfer and vessel preparation with a DCB requires different technique than stent deployment, and health systems adopting DCB technology for the first time must invest in physician training that adds friction to the adoption pathway even where reimbursement and clinical evidence both support use.

These factors substantially limit drug eluting balloon catheters market growth over the forecast period.

Based on drug type, the global drug eluting balloon catheters market is segmented into paclitaxel-coated and sirolimus/limus-eluting balloons. Paclitaxel-coated balloons hold the largest revenue share, because they represent the most established drug class across both the coronary and peripheral segments of the category, anchored by Boston Scientific's AGENT and comparable peripheral platforms, which suits a market where established clinical evidence still commands the largest revenue share. Sirolimus and limus-eluting balloons are expected to register the fastest revenue growth rate in the global drug eluting balloon catheters market over the forecast period, driven by Cordis' SELUTION SLR sustained limus release platform extending into new peripheral and below-the-knee indications, which is why manufacturers are increasingly developing limus-based alternatives alongside their established paclitaxel-coated product lines.

Peripheral artery disease application is expected to account for the largest revenue share in the global drug eluting balloon catheters market during the forecast period

Based on application, the global drug eluting balloon catheters market is segmented into coronary artery disease, peripheral artery disease, and below-the-knee arterial disease. Peripheral artery disease holds the largest revenue share, because DCB technology has been established in the superficial femoral and popliteal artery indication considerably longer than the newer coronary indication, which suits a market where the more mature application still commands the largest share of current procedure volume. Coronary artery disease is expected to register the fastest revenue growth rate in the global drug eluting balloon catheters market over the forecast period, driven by AGENT's FDA approval and subsequent CMS reimbursement support, which is why this newly opened US indication represents the category's single largest incremental growth opportunity.

Sustained limus release coating technology is expected to account for a significantly large revenue share in the global drug eluting balloon catheters market during the forecast period

Based on coating technology, the global drug eluting balloon catheters market is segmented into FreePac, TransPac, and sustained limus release coating technologies. FreePac coating technology holds an established position anchored by Boston Scientific's AGENT platform, which ties directly back to the paclitaxel drug-class dominance described in the market's primary demand driver. Sustained limus release coating technology is expected to register the fastest revenue growth rate in the global drug eluting balloon catheters market over the forecast period, driven by Cordis' SELUTION SLR platform's expanding peripheral clinical dataset, which is why the technology is increasingly positioned as the differentiated alternative to paclitaxel-based coating chemistry.

Based on regional analysis, the drug eluting balloon catheters market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA approval activity and CMS reimbursement infrastructure creates a direct clinical-to-commercial pathway that other regions lack, and because Boston Scientific, Medtronic, and Cordis all maintain their primary commercial presence in the US market. The August 2025 CMS New Technology Add-on Payment designation specifically strengthens the US market's growth trajectory relative to regions without comparable reimbursement mechanisms. The concentration of FDA and CMS activity in the country also means new coronary DCB indications are typically established in the United States first, before comparable frameworks develop elsewhere.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. DCB technology has a longer established history in Europe than in the United States, with CE Mark approval for peripheral applications preceding US coronary approval by more than a decade. The result is steady rather than rapid growth, shaped more by the category's relative maturity in the region than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising cardiovascular and peripheral artery disease incidence and expanding domestic manufacturing capacity. Japan's earlier regulatory approval pathway for DCB technology in the region leaves more room for continued growth than in the newly-opened but still-developing US coronary market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with private hospital networks driving early adoption of DCB technology among higher-income patients. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised coating materials and catheter components that Latin American device distributors depend on, an effect expected to run through 2026 and slow drug eluting balloon catheter adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital network and the UAE's regional distribution hubs represent the primary investment centres for drug eluting balloon catheter adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the interventional cardiology and vascular surgery infrastructure needed to support DCB technology at scale.